Publications by authors named "Per Karlen"

Claim this Profile
L
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén

Therap Adv Gastroenterol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
Carl Eriksson, Isabella Visuri, Lina Vigren, Linda Nilsson, Anders Kärnell

Scand J Gastroenterol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén

Therap Adv Gastroenterol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Sara Rundquist, Carl Eriksson, Linda Nilsson, Leif Angelison, Susanna Jäghult

Scand J Gastroenterol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk

Scand J Gastroenterol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
Michael Eberhardson, Per Karlén, Ludvig Linton, Petra Jones, Annelie Lindberg

J Crohns Colitis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.
Lena Oxelmark, Annelie Lindberg, Robert Löfberg, Berit Sternby, Anders Eriksson

Eur J Gastroenterol Hepatol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study.
Annelie Lindberg, Bjöörn Fossum, Per Karlen, Lena Oxelmark

BMC Complement Altern Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naïve T cells in the gut: how to really find them?
Mats Karlsson, Ludvig Linton, Maria Lampinen, Per Karlén, Hans Glise

Scand J Gastroenterol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease.
Mats Karlsson, Ludvig Linton, Maria Lampinen, Per Karlén, Hans Glise

Scand J Gastroenterol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesalazine-induced renal calculi.
Henrik Jacobsson, Jaran Eriksen, Per Karlén

Am J Case Rep· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory bowel disease professionals' attitudes to and experiences of complementary and alternative medicine.
Annelie Lindberg, Britt Ebbeskog, Per Karlen, Lena Oxelmark

BMC Complement Altern Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis.
Michael Eberhardson, Per Marits, Martina Jones, Petra Jones, Per Karlen

Clin Immunol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Satish Keshav, Tomáš Vaňásek, Yaron Niv, Robert Petryka, Stephanie Howaldt

PLoS One· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD.
Ludvig Linton, Mats Karlsson, Jeanette Grundström, Eric Hjalmarsson, Annelie Lindberg

Clin Transl Gastroenterol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.
Mats Sjöberg, Andrea Walch, Mina Meshkat, Anders Gustavsson, Gunnar Järnerot, Per Karlen

Inflamm Bowel Dis· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colitis-associated DNA aneuploidy and dysplasia in Crohn's disease and risk of colorectal cancer.
Sverre Söderlund, Bernhard Tribukait, Åke Öst, Olle Broström, Per Karlén

Inflamm Bowel Dis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.
Annelie Lindberg, Michael Eberhardson, Mats Karlsson, Per Karlén

BMC Gastroenterol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.
Sverre Söderlund, Fredrik Granath, Olle Broström, Per Karlén, Robert Löfberg

Gastroenterology· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Guidelines don't cover the therapeutic needs for everyone with inflammatory bowel disease].
Stefan Lindgren, Mikael Lördal, Per Karlén

Lakartidningen· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Colitis cancer--myth or reality?].
Erik Hertervig, Ragnar Befrits, Anders Ekbom, Per Karlén, Jan Lindberg

Lakartidningen· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease.
Sverre Söderlund, Lena Brandt, Annika Lapidus, Per Karlén, Olle Broström

Gastroenterology· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sentinel node technique is useful for studies of intestinal immunology in inflammatory bowel disease patients.
Michael Eberhardson, Kenneth Lindberg, Mats Karlsson, Per Karlén, Ola Winqvist

Eur J Gastroenterol Hepatol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
Per M Hellström, Daniel Schmidt, Per Karlén

Lakartidningen· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.
Tryggve Ljung, Ole Østergaard Thomsen, Morten Vatn, Per Karlén, Lars Norman Karlsen

Scand J Gastroenterol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis